ERCC1、K-ras、TP-73在替雷利珠单抗联合TP化疗方案治疗非小细胞肺癌中的评估价值  

An Evaluation of Values of ERCC1,K-ras and TP-73 in Tirelizumab Combined with GP Chemotherapy Regimen

作　　者：王亚飞[1] 张振军[1] 宋长亮[1] 杨琼[1] WANG Yafei;ZHANG Zhenjun;SONG Changliang;YANG Qiong(Cancer Department I,Handan Central Hospital,Handan 056006,China)

机构地区：[1]邯郸市中心医院肿瘤一科,河北邯郸056006

出　　处：《标记免疫分析与临床》2024年第3期496-501,共6页Labeled Immunoassays and Clinical Medicine

基　　金：河北省医学科学研究课题(编号:20200192)。

摘　　要：目的研究探讨核苷酸切除修复交叉互补基因1(ERCC1)、Kirsten-Rous肉瘤病毒蛋白(K-ras)、肿瘤蛋白P73(TP73)在替雷利珠单抗结合紫杉醇+顺铂(TP)化疗方案治疗NSCLC中的评估价值。方法选取2020年1月至2021年12月本院收治的126例NSCLC肺癌患者为研究对象,按随机抽签法分为对照组、观察组,各63例。对照组以TP化疗方案治疗,观察组增加替雷利珠单抗治疗。评估组间临床疗效、肿瘤标记蛋白、免疫指标、生存周期、不良反应。结果观察组患者的客观缓解率为69.84%(44/63)高于对照组患者为52.38%(33/63),观察组疾病控制率为82.54%(52/63),高于对照组患者为66.67%(42/63)(P<0.05)。化疗1周期、化疗3周期、化疗6周期时,观察组ERCC1、K-ras、TP-73水平均低于对照组(P<0.05)。治疗后观察组免疫功能补体C3、补体C4、CD40细胞低于对照组,NK细胞高于对照组(P<0.05)。观察组患者的TTP、PFS、总生存期均高于对照组(P<0.05)。观察组不良反应发生率为19.05%(12/63),对照组为12.70%(8/63),组间比较差异无统计学意义(P>0.05)。结论替雷利珠单抗联合TP化疗方案治疗肺癌有良好的治疗效果,能够改善患者免疫功能,延长患者生存周期,治疗安全性较好,且ERCC1、K-ras、TP-73水平变化可反映替雷利珠单抗联合TP化疗方案在肺癌治疗中的效果,在综合疗效评估中有较高的应用价值。Objective The study aims to evaluate values of nucleotide excision repair cross complementary gene 1(ERCC1),Kirsten Rous sarcoma virus protein(K-ras)and tumor protein P73(TP73)in the treatment of(non-small cell lung cancer,NSCLC)with tirelizumab combined with paclitaxel+cisplatin(TP)chemotherapy regimen.Methods 126 NSCLC patients admitted to our hospital from January,2021 to December,2021 were selected as the subjects and randomly divided into a control group and an observation group,with 63 cases in each group.The control group was treated with TP chemotherapy regimen,while the observation group was treated with tirelizumab.We evaluated the clinical efficacy,tumor marker proteins,immune indicators,survival cycle,and adverse reactions between these two groups.Results The objective response rate of the observation group patients was 69.84%(44/63),which was higher than that of the control group patients(52.38%(33/63).The disease control rate of the observation group was 82.54%(52/63),and it was higher than that of the control group patients(66.67%(42/63)(P<0.05).At cycle 1,cycle 3,and cycle 6 of chemotherapy,levels of ERCC1,K-ras,and TP-73 in the observation group were lower than those in the control group(P<0.05).After treatment,the immune function of complement C3,complement C4,and CD40 cells in the observation group were lower than those in the control group,while NK cells were higher than those in the control group(P<0.05).TTP,PFS,and overall survival of the observation group patients were higher than those of the control group(P<0.05).The incidence of adverse reactions was 19.05%(12/63)in the observation group and 12.70%(8/63)in the control group,with no significant difference between the groups(P>0.05).Conclusion The combination of tirelizumab and TP chemotherapy regimen has a good therapeutic effect in the treatment of lung cancer,which can improve patient immune function,prolong patient survival cycle,and have a good treatment safety.Moreover,changes in ERCC1,K-ras,and TP-73 levels can reflect the therapeut

关 键 词：替雷利珠单抗 紫杉醇 顺铂 核苷酸切除修复交叉互补基因1 基因Kirsten-Rous肉瘤病毒蛋白 肿瘤蛋白P73 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]